clinical-trial
-
Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing â what do we know for sure?
-
Details emerge of first Huntingtonâs disease gene therapy clinical trial
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a âsingle-shotâ virus delivery system.
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
-
Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
-
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
A new way of thinking about trials to prevent Huntington's disease
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-
Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
New study reveals a potential HD biomarker
A potential HD biomarker has been uncovered in a recent clinical study
By Dr Leora Fox -
FDA approves a new drug for symptoms of Huntington's disease
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease